Overview

Titration Study of ABX-1431

Status:
Completed
Trial end date:
2019-05-07
Target enrollment:
Participant gender:
Summary
This study is designed to identify a titration regimen of ABX-1431 in adults with neuropathic pain with satisfactory tolerability to central nervous system (CNS) adverse events (AEs). During the course of this study, each participant will take a daily dose of ABX-1431 or a matching placebo for 28 days.
Phase:
Phase 1
Details
Lead Sponsor:
Abide Therapeutics